Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

MAIA vs RLMD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MAIA Captures Overall Composite Edge (37.6 SELL vs 47.6 HOLD), While RLMD Leads 3–2 on Growth & Valuation Pillars

MAIA Overall Winner 6-Pillar Tally: MAIA 2 – 3 RLMD (1 Tie) Matrix Metrics: MAIA 4 – 3 RLMD

As of Nov 20, 2026, MAIA Biotechnology, Inc. (MAIA) captures the overall head-to-head institutional edge over Relmada Therapeutics, Inc. (RLMD) on higher Unified Composite conviction (37.6/100 SELL vs. 47.6/100 HOLD) after splitting the core matrix 4–3 (led by Valuation Multiples, Options & Positioning), while RLMD wins 3–2 across the 6-pillar growth and valuation breakdown. MAIA trades at $1.11 (1.2x Forward P/E, 0.0% operating margin) versus RLMD at $2.62 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While RLMD currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. MAIA 37.6/100 SELL), MAIA captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY).
  • Technical & Structure Timing Caution: MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8); meanwhile RLMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MAIA vs RLMD
MAIA NYSE American Head-to-Head Winner
MAIA Biotechnology, Inc.
Pharmaceutical Preparations
$1.11
-2.63% 1D
Market Cap $68.5M
TTM Revenue N/A
Forward P/E 1.2x
Beta / 30D Vol 1.65β · 108% Vol
Unified Composite Score
37.6 / 100 SELL
Tech 40.0 Fund 38.0 Flow 50.0 Mom 44.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 49
RSI-14: 48.8 · SMA20: $1.11 · SMA50: $1.17
RLMD NASDAQ
Relmada Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$2.62
-15.76% 1D
Market Cap $331.8M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 1.67β · 120% Vol
Unified Composite Score
47.6 / 100 HOLD
Tech 40.0 Fund 51.0 Flow 68.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -8.5%), weak momentum, RSI 34
RSI-14: 34.2 · SMA20: $3.66 · SMA50: $3.64

6-Pillar Scorecard Institutional Category Breakdown (MAIA 2 – 3 RLMD)

Columns: Metric · MAIA · RLMD
1. Valuation Multiples MAIA
Forward P/E 1.2x N/M
Trailing P/E 1.2x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale RLMD
Revenue Growth (YoY) +0.0% +0.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $68.5M $331.8M
3. Profitability & Quality RLMD
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -341.5% -64.7%
4. Balance Sheet & Cash Flow RLMD
Cash Generation (TTM) -$20M -$52M
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.24 Book/Sh · -341.5% ROE $1.82 Book/Sh · -64.7% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MAIA
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 64.4% (16th %ile)
Put/Call OI Skew N/A 0.07x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MAIA (4) vs RLMD (3)
Institutional Metric MAIA RLMD Criterion Row Edge
Market Capitalization
Scale
$68.5M $331.8M Larger Scale RLMD
Trailing P/E Ratio
Valuation
1.2x N/M Lower Multiple MAIA
Forward P/E Ratio
Valuation
1.2x N/M Lower Multiple MAIA
Revenue Growth (YoY)
Growth
+0.0% +0.0% Higher Growth Tie
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-341.5% -64.7% Higher ROE RLMD
52-Week Range Position
Momentum
10% ($1–$3) 0% ($3–$8) Stronger Trend MAIA
Beta / 30D Volatility
Risk Regime
1.65β · 108% Vol 1.67β · 120% Vol Lower Realized Risk MAIA
Unified Institutional Score
Composite Signal
37.6 / 100 (SELL) 47.6 / 100 (HOLD) Higher Composite RLMD
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$20M ($0.24 Book/Sh · -341.5% ROE) -$52M ($1.82 Book/Sh · -64.7% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MAIA +18.59 pp
MAIA: -1.77% · RLMD: -20.36%
3M Horizon MAIA +25.01 pp
MAIA: -17.78% · RLMD: -42.79%
6M Horizon MAIA +49.5 pp
MAIA: -13.28% · RLMD: -62.78%
1Y Horizon MAIA +57.97 pp
MAIA: +20.65% · RLMD: -37.32%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MAIA vs RLMD. Trailing 12-month operating profitability (MAIA 0.0% vs RLMD 0.0%) and valuation multiples (MAIA 1.2x vs RLMD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MAIA ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-341.5% · 1.2x
RLMD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-64.7% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MAIA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MAIA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RLMD BREAKDOWN
7d in phase · OBV DISTRIBUTION
Current IV 64.4%
IV Percentile 16th %ile
Put/Call OI Skew 0.07x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact RLMD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MAIA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $68.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RLMD Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $331.8M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MAIA vs RLMD Key Questions & Quantitative Answers

As of Nov 20, 2026, MAIA Biotechnology, Inc. (MAIA) captures the overall head-to-head institutional edge over Relmada Therapeutics, Inc. (RLMD) on higher Unified Composite conviction (37.6/100 SELL vs. 47.6/100 HOLD) after splitting the core matrix 4–3 (led by Valuation Multiples, Options & Positioning), while RLMD wins 3–2 across the 6-pillar growth and valuation breakdown. MAIA trades at $1.11 (1.2x Forward P/E, 0.0% operating margin) versus RLMD at $2.62 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While RLMD currently prints a higher short-term Unified Composite Score (47.6/100 HOLD vs. MAIA 37.6/100 SELL), MAIA captures the overall institutional head-to-head verdict (4–3 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +0.0% YoY). Technical & Structure Timing Caution: MAIA trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 48.8); meanwhile RLMD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 34.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

RLMD leads the Growth & Scale pillar: MAIA posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with RLMD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, MAIA generates N/A in USD-normalized revenue versus N/A for RLMD. In operating R&D and SG&A reinvestment, MAIA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RLMD.

MAIA screens cheaper on headline valuation multiples. MAIA trades at 1.2x Forward P/E, 1.2x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas RLMD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MAIA (-341.5% ROE) versus RLMD (-64.7% ROE) capital efficiency.

In options market volatility and institutional positioning, MAIA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.65β · 108% Vol realized risk). By comparison, RLMD carries 64.4% implied volatility (16th %ile, Compressed (<25th %ile)), a 0.07x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (1.67β · 120% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.